Citation Impact
Citing Papers
Architecture of the Photosynthetic Oxygen-Evolving Center
2004 StandoutScience
Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum
2023 Standout
Immunomodulatory Function of Interleukin 28B During Primary Infection With Cytomegalovirus
2014 StandoutNobel
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA)
2014 Standout
The Second Canadian Symposium on Hepatitis C Virus: A Call to Action
2013 StandoutNobel
Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir"
2015
Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines
2013 StandoutNobel
Glycosylation diseases: Quo vadis?
2008
Natural products: An evolving role in future drug discovery
2011 Standout
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
2015
Mechanotransduction and extracellular matrix homeostasis
2014 Standout
Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?
2012
Mixed HCV infection and reinfection in people who inject drugs—impact on therapy
2015
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Recent Progress in the Crystallographic Studies of Photosystem II
2010 StandoutNobel
New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives
2012
Function of Redox-Active Tyrosine in Photosystem II
2006
Biological roles of glycans
2016 Standout
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Interferon-based therapy of hepatitis C
2007
Interferon-based therapy for chronic hepatitis C: current and future perspectives
2008
Amino acid residues that modulate the properties of tyrosine YZ and the manganese cluster in the water oxidizing complex of photosystem II
2001
Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients
2015
Expert opinion on the treatment of patients with chronic hepatitis C
2008
Glycotherapy: New Advances Inspire a Reemergence of Glycans in Medicine
2013 StandoutNobel
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
2011
A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin
2010
The extrinsic proteins of Photosystem II
2007
IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza
2014 StandoutNobel
Towards complete cofactor arrangement in the 3.0 Å resolution structure of photosystem II
2005 StandoutNature
The extrinsic proteins of Photosystem II
2011
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Early and Accurate Prediction of Peg-IFNs/Ribavirin Therapy Outcome in the Individual Patient With Chronic Hepatitis C by Modeling the Dynamics of the Infected Cells
2008
Optimal therapy in genotype 1 patients
2009
Taming a beast: lessons from the domestication of hepatitis C virus
2019 StandoutNobel
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
Innate Immune Responses to Hepatitis C Virus
2013 StandoutNobel
Loss of function of the new interferon IFN-λ4 may confer protection from hepatitis C
2013
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen–negative patients with chronic hepatitis B
2012
Elastic fibres in health and disease
2013
A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry
2014 Standout
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Modifications of Glycans: Biological Significance and Therapeutic Opportunities
2011
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry
2016 StandoutNobel
Current Perspectives on the Use of Alternative Species in Human Health and Ecological Hazard Assessments
2013
Antisense Gets a Grip on miR-122 in Chimpanzees
2010 StandoutNobel
An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the Liver
2012
Development of a multiplex phenotypic cell-based high throughput screening assay to identify novel hepatitis C virus antivirals
2013 StandoutNobel
Update of the Belgian Association for the Study of the Liver guidelines for the treatment of chronic hepatitis C genotype 1 with protease inhibitors.
2012
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
2015 StandoutNobel
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents
2014 StandoutNobel
2013 StandoutNobel
Boceprevir in chronic hepatitis C infection: a perspective review
2012
Towards a small animal model for hepatitis C
2009 StandoutNobel
Transition‐Metal (Co, Ni, and Fe)‐Based Electrocatalysts for the Water Oxidation Reaction
2016 Standout
Internal Disequilibria and Phenotypic Diversification during Replication of Hepatitis C Virus in a Noncoevolving Cellular Environment
2017 StandoutNobel
Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
2016 StandoutNobel
Association Between Electronic Health Record Time and Quality of Care Metrics in Primary Care
2022
Effects of Inactivating psbM and psbT on Photodamage and Assembly of Photosystem II in Synechocystis sp. PCC 6803
2008
Proton-Coupled Electron Transfer
2012 Standout
Human Genetic Disorders and Knockout Mice Deficient in Glycosaminoglycan
2014
Works of Tim Morgan being referenced
Spondyloepiphyseal dysplasia, Omani type: Further definition of the phenotype
2008
Craniosynostosis and Multiple Skeletal Anomalies in Humans and Zebrafish Result from a Defect in the Localized Degradation of Retinoic Acid
2011
Further expansion of the phenotypic spectrum associated with mutations in ALDH18A1, encoding Δ1‐pyrroline‐5‐carboxylate synthase (P5CS)
2011
Hepatitis C Care in the Department of Veterans Affairs
2018
[8] SHOULD TREATMENT WITH PEGINTERFERON PLUS RIBAVIRIN BE INTENSIFIED IN PATIENTS WITH HCV GENOTYPE 2/3 WITHOUT A RAPID VIROLOGICAL RESPONSE?
2007
12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY
2011
O111 SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1–6 HCV INFECTION
2014
101 INCIDENCE RATES AND RISK FACTORS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH ADVANCED LIVER DISEASE DUE TO HEPATITIS C: RESULTS OF THE HALT-C TRIAL
2008
744 Sustained virologic response (SVR) to interferon-alpha-2b +/- ribavirin therapy at 6 months reliably predicts long-term clearance of HCV at 5-year follow-up
2006
Specific Requirements for Cytochrome c-550 and the Manganese-Stabilizing Protein in Photoautotrophic Strains of Synechocystis sp. PCC 6803 with Mutations in the Domain Gly-351 to Thr-436 of the Chlorophyll-Binding Protein CP47
1998
LP01 : Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1-4 in HIV-HCV coinfection: The ALLY-2 study
2015